Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afamelanotide - Clinuvel Pharmaceuticals

X
Drug Profile

Afamelanotide - Clinuvel Pharmaceuticals

Alternative Names: [Nle4,DPhe7]-alpha-MSH; Afamelanotide acetate; CUV-1647; EPT-1647; Melanotan I; Melanotan™; MT I; PRENUMBRA; Scenesse; Scenesse® Enfance

Latest Information Update: 21 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Arizona
  • Developer Clinuvel Pharmaceuticals; Winhealth Pharma
  • Class Antiacnes; Antineoplastics; Antipyretics; Melanocyte-stimulating hormones; Peptides; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Melanocortin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythropoietic protoporphyria; Pemphigus; Urticaria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythropoietic protoporphyria
  • Phase III Polymorphus light eruptions; Vitiligo
  • Phase II Hepatic-porphyria; Pemphigus; Stroke; Xeroderma pigmentosum
  • Preclinical Parkinson's disease
  • Suspended Urticaria
  • Discontinued Acne vulgaris; Actinic keratosis; Photodamage; Squamous cell cancer

Most Recent Events

  • 18 Jun 2024 Preclinical trials in Parkinson's disease in Australia (unspecified route) prior to June 2024
  • 18 Jun 2024 Clinuvel Pharmaceuticals receives ethics and regulatory approval to initiate the phase IIa CUV901 trial in Parkinson’s disease
  • 18 Jun 2024 Pharmacodynamics data from preclinical studies in Parkinson’s disease were released by Clinuvel Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top